Inovio Pharmaceuticals stock analysis
Want to see INO full AI Analyst Report?
Inovio Pharmaceuticals (INO) Stock Price & Analysis
INO Stock Chart & Stats
- Day’s Range
- $1.63 - $1.79
- 52-Week Range
- $0.56 - $2.72
- Previous Close
- $1.69
- Volume
- N/A
- Average Volume (3M)
- 19.60M
- Market Cap
- $320.29M
- Enterprise Value
- $79.25M
- Total Cash (Recent Filing)
- $48.36M
- Total Debt (Recent Filing)
- $7.28M
- Price to Earnings (P/E)
- ―
- Beta
- 0.83
- Next Earnings
- Mar 02, 2027 (Est.)
- EPS Estimate
- -0.13
- Last Dividend Ex-Date
- Sep 28, 2017
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
First Approved Product
FDA approval moves Inovio from a development-stage biotechnology company toward commercial operations and validates its DNA medicine and CELLECTRA delivery platform. It creates an approved product base from which the company can pursue U.S. sales, additional indications, and international expansion.
Durable Clinical Benefit
Reported reductions in surgery, durable benefit through year three, and supportive immune-response findings strengthen the product’s clinical differentiation. If confirmed, this profile could support sustained physician adoption and improve the durability of VOCERYQ’s commercial opportunity.
Launch Readiness And Market Reach
The planned field organization, payer-support capabilities, manufacturing capacity, and identified RRP population provide a defined path to commercialization. Coverage focused on major institutions and integrated networks should help the company reach concentrated patient populations efficiently after launch.
Bears Say
Confirmatory Approval Risk
Accelerated approval leaves the product’s long-term regulatory status dependent on additional evidence. The required study must enroll patients and track surgical outcomes for at least three years, creating execution, timing, and potential approval risk that could affect the commercial opportunity.
Escalating Cash Burn
Persistent and worsening cash consumption means Inovio must fund operations while simultaneously building its commercial organization. Continued negative cash flow can restrict investment flexibility and increase reliance on financing before product revenue becomes sufficiently established.
Negative Equity And Financing Risk
Deeply negative equity signals a materially weakened balance sheet after prolonged losses and limits the company’s ability to absorb further operating shortfalls. Financing may therefore be needed on unfavorable terms, increasing dilution risk as Inovio funds launch and development activities.
Inovio Pharmaceuticals News
INO FAQ
What was Inovio Pharmaceuticals’s price range in the past 12 months?
What is Inovio Pharmaceuticals’s market cap?
When is Inovio Pharmaceuticals’s upcoming earnings report date?
How were Inovio Pharmaceuticals’s earnings last quarter?
Is Inovio Pharmaceuticals overvalued?
Does Inovio Pharmaceuticals pay dividends?
What is Inovio Pharmaceuticals’s EPS estimate?
How many shares outstanding does Inovio Pharmaceuticals have?
What happened to Inovio Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Inovio Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Inovio Pharmaceuticals Stock Smart Score
Company Description
Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jacqueline E. Shea
- Employees
- 112
- Website
- www.inovio.com
- Address
- 660 West Germantown Pike, Plymouth Meeting, PA, 19462, US
Inovio Pharmaceuticals (INO) Earnings & Revenues
INO Company Deck
INO Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, driven by FDA approval of VOCERYQ, reported reductions in surgery, durable clinical benefit, a favorable tolerability profile, a large identified RRP population, launch preparations and funding projected to support operations into late fourth quarter 2027. The principal challenges were the conditional nature of Accelerated Approval, the need for a confirmatory study, continued cash burn, a higher reported net loss driven by non-cash warrant adjustments, and funding limitations in some international markets.
View all INO earnings summariesINO Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 5 | 2 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 12 | 0 | 0 |












